TARGETED OUTREACH & VISIBILITY
Visibility Needs to Be Intentional
Clinical-stage biotech companies need visibility but not just more visibility. What matters is reaching the right audience, at the right time, with the right message.
Effective visibility requires alignment between audience, message, timing, and channel.
Many companies struggle to clearly answer:
Are you reaching the right investors and partners?
Is your visibility aligned with key milestones and data releases?
Are you being seen in the right contexts?
Does your outreach reinforce your positioning and narrative?
Without targeted visibility, even strong programs can go unnoticed by the audiences that matter most.
The Biotech Challenges
- Untargeted Visibility Efforts
Efforts are often broad and unfocused, reaching audiences that are not relevant to the company’s goals.
- Poor Timing of Exposure
Visibility is not aligned with key milestones such as data releases, fundraising, or partnering activities.
- Low Visibility Among Priority Stakeholders
Important updates and announcements are lost in a crowded information landscape.
- Misalignment with Positioning
Visibility efforts are not clearly tied to the company’s narrative or strategic positioning.
- Inefficient Use of Budget
Resources are spent without clear targeting or measurable impact.
- Lack of Coordination
Campaigns are executed in isolation rather than as part of a cohesive visibility strategy.
The Bowei Solutions
Targeted Campaign Strategy
We design visibility campaigns that focus on reaching specific, high-value audiences aligned with your goals.
Audience & Channel Targeting
We identify where your key audiences are and ensure your company appears in the right channels and contexts.
Milestone-Driven Campaign Planning
We align visibility efforts with key moments – such as data releases, fundraising, and BD activities – to maximize impact.
Message & Campaign Alignment
We ensure that every campaign reinforces your positioning, narrative, and strategic priorities.
Case Study
The Situation
A U.S.-based oncology biotech company developing a Phase II antibody-drug conjugate (ADC) was preparing to announce new clinical data. Despite the importance of the update, the company struggled to reach relevant biotech investors and potential partners.
Key challenges included:
- limited visibility among target investor and BD audiences
- untargeted outreach across digital channels
- lack of alignment between communication efforts and the timing of the data release
Our Approach
We developed a targeted visibility campaign aligned with the upcoming clinical data announcement.
This included:
- defining priority audience segments, including oncology-focused biotech investors and pharmaceutical BD teams
- executing targeted campaigns across LinkedIn and Google to reach relevant stakeholders
- aligning messaging and campaign timing with the data release to maximize visibility and engagement
The Outcome
With a more focused and well-timed campaign, the company significantly improved how its clinical update was seen and engaged with.
This resulted in:
increased visibility among targeted oncology investors and BD teams during the data release window
higher engagement rates across campaign channels compared to prior announcements
increased inbound interest and follow-up conversations from relevant stakeholders
improved alignment between campaign performance and business development activity
Reach the Right Audience When It Matters Most
Visibility is not about volume – it’s about precision.
We help clinical-stage biotech companies ensure their message reaches the audiences that matter most, when it matters most.